The integration of advanced technologies, such as basal insulin therapy (PwT2D-BI) and continuous glucose monitoring (CGM), has shown significant promise in improving glycemic control for individuals with type 2 diabetes (T2D). Here, INS is linked to type 2 diabetes mellitus.